CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease Coronary Microcirculation in Ischemic Heart Disease Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease Left Main Revascularization in 2017: Coronary Artery Bypass Grafting or Percutaneous Coronary Intervention? Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

GuidelineJune 13, 2019

JOURNAL:JAMA Article Link

Primary Prevention of Sudden Cardiac Death

A D. Beaser; Adam S. Cifu, MD; Hemal M. Nayak. Keywords: rhythem dysorder; sudden cardiac death; primary prevention; LVEF; heart failure; ventricular fibrillation

ABSTRACT

Ventricular arrhythmias range from benign premature ventricular contractions to ventricular fibrillation and can be asymptomatic or have sudden cardiac death as the first manifestation. Sudden cardiac death is a major public health problem, accounting for 50% of all cardiovascular death.1 Although a plurality of sudden cardiac death occurs in the general population with no apparent cardiac risk factors, the risk is greatest in patients with LVEF of less than 30%, clinical heart failure, prior aborted cardiac arrest, or coronary artery disease.2